You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 9, 2025

Claims for Patent: 10,561,651

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,561,651

Title:	Methods for treating neuroblastoma
Abstract:	Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.
Inventor(s):	Lim; Jonathan (San Diego, CA), Ardini; Elena (Sesto san Giovanni, IT), Menichincheri; Maria (Milan, IT)
Assignee:	IGNYTA, INC. (San Diego, CA) NERVIANO MEDICAL SCIENCES, S.R.L. (Nerviano (MI), IT)
Application Number:	16/050,516
Patent Claims:	1. A method of inhibiting deregulated protein kinase activity in a neuroblastoma cell, wherein said deregulated protein kinase activity is one or more of tyrosine kinase ROS1, high affinity receptor tyrosine kinase TrkA, TrkB, or TrkC activity, the method comprising administering to said cell an effective amount of a compound as the sole active agent selected from the group consisting of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahyd- ro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-m- ethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)benzamide, and a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahyd- ro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein the compound is N-[5-(3,5-difluoro -benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-- 4-(4-methyl -piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein said deregulated protein kinase activity is activity of ROS1. 6. The method of claim 1, wherein said deregulated protein kinase activity is activity of TrkA. 7. The method of claim 1, wherein said deregulated protein kinase activity is activity of TrkB. 8. The method of claim 1, wherein said deregulated protein kinase activity is activity of TrkC.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.